Skip to Content

Roche Holding AG ADR RHHBY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Stewardship

PREMIUM

Trump's Executive Orders on Drug Prices Have Limited Impact on Our Industry FVEs and Moat Ratings

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

President Donald Trump’s executive orders targeting drug prices create modest pricing headwinds and slightly higher uncertainty for drug firms. However, we don’t expect these actions to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.

Read Full Analysis

Company Profile

Business Description

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 60% of pharmaceutical sales, and professional diagnostics for more than half of diagnostic-related sales.

Contact
c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124
Basel, CH-4070, Switzerland
T +41 616881111
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees 97,735

Related